Caroline J. Breitbach

6.1k citations

51 papers · 3.5k indexed · 1 hit paper · h-index 28

Genetics top 0.5%
Oncology top 1%
Molecular Biology top 10%
Immunology top 2%
Biotechnology top 0.5%

Co-authors: John C. Bell David H. Kirn Brian D. Lichty David F. Stojdl James M. Burke Tae-Ho Hwang Anne Moon Theresa Falls
Topics: Virus-based gene therapy research (42 papers)CAR-T cell therapy research (25 papers)Cancer Research and Treatments (19 papers)
Cited by: Genetics Oncology Biotechnology
Journals: Nature Proceedings of the National Academy of Sciences Journal of Clinical Oncology
Partner nations: Canada United States South Korea

In The Last Decade

Caroline J. Breitbach

49 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Going viral with cancer immunotherapy

2014 481 citations Brian D. Lichty, Caroline J. Breitbach et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Caroline J. Breitbach

Since Specialization

Citations

This map shows the geographic impact of Caroline J. Breitbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caroline J. Breitbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caroline J. Breitbach more than expected).

Fields of papers citing papers by Caroline J. Breitbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caroline J. Breitbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caroline J. Breitbach. The network helps show where Caroline J. Breitbach may publish in the future.

Co-authorship network of co-authors of Caroline J. Breitbach

This figure shows the co-authorship network connecting the top 25 collaborators of Caroline J. Breitbach. A scholar is included among the top collaborators of Caroline J. Breitbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caroline J. Breitbach. Caroline J. Breitbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma 2024 ·Cancer Research Communications ·Todd Shearer,(unknown),(unknown),Mark C. Johnson,Ewa Cendrowicz,(unknown),Margaret Smith,(unknown),Caroline J. Breitbach,Shinta Cheng,Damian J. Green	0
2	Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284) 2023 ·Gynecologic Oncology ·Panagiotis A. Konstantinopoulos,(unknown),Todd Shearer,(unknown),Caroline J. Breitbach,Shinta Cheng	2
3	Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms 2017 ·Cancer Research ·Minah Kim,Maximilian Nitschké,Barbara Sennino,Patrizia Murer,Brian J. Schriver,(unknown),(unknown),(unknown),Jiahu Wang,(unknown),Marie‐Claude Bourgeois‐Daigneault,David H. Kirn,John C. Bell,Naomi De Silva,Caroline J. Breitbach,Donald M. McDonald	55
4	Oncolytic Viruses: Therapeutics With an Identity Crisis 2016 ·EBioMedicine ·Caroline J. Breitbach,Brian D. Lichty,John C. Bell	78
5	The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594) 2015 ·PubMed ·Caroline J. Breitbach,John C. Bell,Tae-Ho Hwang,David H. Kirn,James M. Burke	46
6	Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer 2015 ·Molecular Therapy ·Se Hoon Park,Caroline J. Breitbach,Jeeyun Lee,Joon Oh Park,Ho Yeong Lim,Won Ki Kang,Anne Moon,(unknown),(unknown),(unknown),(unknown),Adina Pelusio,James M. Burke,(unknown),David H. Kirn,Young Suk Park	140
7	Oncolytic viruses: perspectives on clinical development 2015 ·Current Opinion in Virology ·James M. Burke,Jorge J. Nieva,Mitesh J. Borad,Caroline J. Breitbach	19
8	Going viral with cancer immunotherapybreakdown → 2014 ·Nature reviews. Cancer ·Brian D. Lichty,Caroline J. Breitbach,David F. Stojdl,John C. Bell	481
9	Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1 2014 ·Frontiers in Oncology ·Markus Moehler,(unknown),Bernd Heinrich,Caroline J. Breitbach,(unknown),Peter R. Galle,Jean Rommelaere	19
10	First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity 2014 ·Molecular Therapy ·Herbert J. Zeh,Stephanie Downs‐Canner,J. Andrea McCart,Zong Sheng Guo,Uma N. M. Rao,Lekshmi Ramalingam,Stephen H. Thorne,Heather Jones,Paweł Kaliński,Eva Wieckowski,Mark E. O’Malley,Manijeh Daneshmand,Kang Hu,John C. Bell,(unknown),Anne Moon,Caroline J. Breitbach,David H. Kirn,David L. Bartlett	120
11	Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans 2013 ·Cancer Research ·Caroline J. Breitbach,Rozanne Arulanandam,Naomi De Silva,Steve H. Thorne,Richard H. Patt,Manijeh Daneshmand,Anne Moon,Carolina S. Ilkow,James M. Burke,Tae-Ho Hwang,Jeong Heo,Mong Cho,Hannah Chen,Fernando A. Angarita,Christina Addison,J. Andrea McCart,John C. Bell,David H. Kirn	208
12	Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells 2012 ·Cancer Research ·Lee‐Hwa Tai,Christiano Tanese de Souza,Simon Bélanger,Lundi Ly,Almohanad A. Alkayyal,Jiqing Zhang,Julia L. Rintoul,Abhirami A. Ananth,Tiffany Lam,Caroline J. Breitbach,Theresa Falls,David H. Kirn,John C. Bell,Andrew P. Makrigiannis,Rebecca C. Auer	187
13	Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594 2012 ·Current Pharmaceutical Biotechnology ·Caroline J. Breitbach,Steve H. Thorne,John C. Bell,David H. Kirn	35
14	A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma 2011 ·Molecular Therapy ·Tae-Ho Hwang,Anne Moon,James M. Burke,Antoni Ribas,Joe Stephenson,Caroline J. Breitbach,Manijeh Daneshmand,Naomi De Silva,Kelley A. Parato,Jean‐Simon Diallo,Yeon-Sook Lee,Ta‐Chiang Liu,John C. Bell,David H. Kirn	122
15	The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers 2011 ·Molecular Therapy ·Kelley A. Parato,Caroline J. Breitbach,Fabrice Le Bœuf,Jiahu Wang,(unknown),Carolina S. Ilkow,Jean‐Simon Diallo,Theresa Falls,Joseph K. Burns,Vanessa da Silva Garcia,Femina Kanji,Laura Evgin,Kang Hu,Francois Paradis,Shane Knowles,Tae-Ho Hwang,Barbara C. Vanderhyden,Rebecca C. Auer,David H. Kirn,John C. Bell	224
16	Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma 2010 ·Molecular Therapy ·Xueqing Lun,Jennifer A. Chan,Hongyuan Zhou,Beichen Sun,John J. Kelly,(unknown),John C. Bell,Kelley A. Parato,Kang Hu,(unknown),Jiahu Wang,Ta‐Chiang Liu,Caroline J. Breitbach,David H. Kirn,Donna L. Senger,Peter Forsyth	77
17	Double trouble for tumours: Exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses 2010 ·Cytokine & Growth Factor Reviews ·Naomi De Silva,Harold Atkins,David H. Kirn,John C. Bell,Caroline J. Breitbach	27
18	Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors 2010 ·PLoS ONE ·(unknown),Jean‐Simon Diallo,(unknown),Marianne M. Stanford,Fabrice Le Bœuf,Naomi De Silva,Julie A. Cox,(unknown),(unknown),Theresa Falls,J. Andrea McCart,Harry Atkins,Caroline J. Breitbach,David H. Kirn,Stephen H. Thorne,John C. Bell	60
19	Efficacy of Systemically Administered Mutant Vesicular Stomatitis Virus (VSVΔ51) Combined with Radiation for Nasopharyngeal Carcinoma 2008 ·Clinical Cancer Research ·Nehad M. Alajez,Joseph D. Mocanu,Wei Shi,Marie C. Chia,Caroline J. Breitbach,Angela B. Hui,Shane Knowles,John C. Bell,Pierre Busson,Kenzo Takada,Kwok Wai Lo,Brian O’Sullivan,Pat Gullane,Fei‐Fei Liu	18
20	Structures of aminoglycoside acetyltransferase AAC(6′)-Ii in a novel crystal form: structural and normal-mode analyses 2005 ·Acta Crystallographica Section D Biological Crystallography ·David L. Burk,Bing Xiong,Caroline J. Breitbach,Albert M. Berghuis	21

About Caroline J. Breitbach

Caroline J. Breitbach is a scholar working on Biotechnology, Genetics and Oncology, having authored 51 papers that have together received 3.5k indexed citations. Recurring topics across this work include Virus-based gene therapy research (42 papers), CAR-T cell therapy research (25 papers) and Cancer Research and Treatments (19 papers). The work is most often cited by research in Genetics (2.5k citations), Oncology (2.1k citations) and Biotechnology (538 citations). Caroline J. Breitbach has collaborated with scholars based in Canada, United States and South Korea. Frequent co-authors include John C. Bell, David H. Kirn, Brian D. Lichty, David F. Stojdl, James M. Burke, Tae-Ho Hwang, Anne Moon, Theresa Falls, Kelley A. Parato and Manijeh Daneshmand. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact